Cancer Biomarkers最新文献_第10页

FKBP11 upregulation promotes proliferation and migration in hepatocellular carcinoma. FKBP11上调促进肝细胞癌的增殖和迁移。

IF 3.1 4区医学

Cancer Biomarkers Pub Date : 2023-01-01 DOI: 10.3233/CBM-220440

Erick Thokerunga, Christian Cedric Bongolo, Simon Peter Rugera, Gilbert Akankwatsa, Jian-Cheng Tu

{"title":"FKBP11 upregulation promotes proliferation and migration in hepatocellular carcinoma.","authors":"Erick Thokerunga, Christian Cedric Bongolo, Simon Peter Rugera, Gilbert Akankwatsa, Jian-Cheng Tu","doi":"10.3233/CBM-220440","DOIUrl":"https://doi.org/10.3233/CBM-220440","url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths world over. Early diagnosis and effective treatment monitoring significantly improves patients' outcomes. FKBP11 gene is highly expressed in HCC and could play a role in its development, early diagnosis and treatment.Objective: This study aimed to evaluate the expression of FKBP11 in HCC, its correlation with patients' clinical characteristics and potential role in HCC development.Methods: Expression was determined by bioinformatics analysis, quantitative real-time PCR, western blot, and immunohistochemistry. CCK-8, Transwell and wound healing assays were used to investigate involvement in HCC development.Results: FKBP11 was significantly upregulated in HCC cells, tissues and blood (all p< 0.001). Its receiver operator characteristic (ROC) curve had an AUC of 0.864 (95% CI: 0.823-0.904), at a sensitivity of 0.86 and specificity of 0.78 indicating a good diagnostic potential in HCC. Its expression was markedly reduced after surgery (p< 0.0001), indicating a potential application in HCC treatment follow-up. Knockdown of FKBP11 in HCC cells attenuated proliferation and migration, suggesting a possible role in HCC pathogenesis.Conclusion: This study thus found that FKBP11 is upregulated in HCC, and the upregulation promotes HCC development. FKBP11 levels are significantly reduced post-surgery and could be a potential diagnostic and prognostic marker for HCC.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"37 2","pages":"109-120"},"PeriodicalIF":3.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9630523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FSCN1 has a potential indication for the prognosis and regulates the migration of HNSCC. FSCN1对HNSCC的预后具有潜在的指示作用，并调节其迁移。

IF 3.1 4区医学

Cancer Biomarkers Pub Date : 2023-01-01 DOI: 10.3233/CBM-220409

Yuliang Zhang, Anyan Zhou, Jiabin Nian, Shuzhou Liu, Xin Wei

{"title":"FSCN1 has a potential indication for the prognosis and regulates the migration of HNSCC.","authors":"Yuliang Zhang, Anyan Zhou, Jiabin Nian, Shuzhou Liu, Xin Wei","doi":"10.3233/CBM-220409","DOIUrl":"10.3233/CBM-220409","url":null,"abstract":"Background: The study of molecular markers for diagnosis and prognosis is of great clinical significance for HNSCC patients. In this study, we proposed that FSCN1 has a potential indication for prognosis and is essential for the migration of HNSCC.Methods: We analyzed the expression and survival association of FSCN1 in HNSCC using TCGA data. We compared the expression of FSCN1 in tumors from primary and metastasis HNSCC patients using QPCR, western blotting, and immunochemistry staining. We determined the migration velocity of multiple HNSCC cell lines using a chemotaxis migration assay. We analyzed the correlation between FSCN1 expression and HNSCC cell migration. We also test the effect of FSCN1 knockdown and overexpression on HNSCC cell migration.Results: FSCN1 was overexpressed in HNSCC than pair normal tissues and metastasis HNSCC than primary HNSCC. FSCN1 expression was associated with significantly poorer overall survival of HNSCC patients. FSCN1 was potentially associated with immune cell infiltration and migration-associated genes. FSCN1 level was correlated with the migration in HNSCC cell lines. Knockdown of FSCN1 reduced the migration and the overexpression of FSCN1 promoted the migration of HNSCC cell lines.Conclusion: FSCN1 is a potential prognostic marker and a critical biomolecule for the migration of HNSCC.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":" ","pages":"161-176"},"PeriodicalIF":3.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9900560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive serum lipidomic analyses reveal potential biomarkers for malignant breast cancer: A case-control study. 全面的血清脂质组学分析揭示了癌症的潜在生物标志物：一项病例对照研究。

IF 3.1 4区医学

Cancer Biomarkers Pub Date : 2023-01-01 DOI: 10.3233/CBM-220462

Bing Cao, Siyu Yang, Lailai Yan, Nan Li

{"title":"Comprehensive serum lipidomic analyses reveal potential biomarkers for malignant breast cancer: A case-control study.","authors":"Bing Cao, Siyu Yang, Lailai Yan, Nan Li","doi":"10.3233/CBM-220462","DOIUrl":"10.3233/CBM-220462","url":null,"abstract":"Background: Breast cancer is the most worldwide commonly found malignancy among women. The evidence for lipidomic studies of breast cancer in the Chinese population is relatively limited.Objective: Our current study aimed to identify peripheral lipids capable of distinguishing adults with and without malignant breast cancer in a Chinese population and to explore the potential lipid metabolism pathways implicated in breast cancer.Methods: Lipidomics was performed with an Ultimate 3000 UHPLC system coupled with a Q-Exactive HF MS platform by using the serum of 71 female patients with malignant breast cancer and 92 age-matched (± 2 years) healthy women. The data were uploaded to and processed by the specialized online software Metaboanalyst 5.0. Both univariate and multivariate analyses were carried out for potential biomarker screening. Areas under the receiver-operating characteristic (ROC) curves (AUCs) of identified differential lipids were obtained for evaluating their classification capacity.Results: A total of 47 significantly different lipids were identified by applying the following criteria: false discovery rate-adjusted P < 0.05, variable importance in projection ⩾ 1.0, and fold change ⩾ 2.0 or ⩽ 0.5. Among them, 13 lipids were identified as diagnostic biomarkers with the area under curve (AUC) greater than 0.7. Multivariate ROC curves indicated that AUCs greater than 0.8 could be achieved with 2-47 lipids.Conclusions: Using an untargeted LC-MS-based metabolic profiling approach, our study provides preliminary evidence that extensive dysregulations of OxPCs, PCs, SMs and TAGs were involved in the pathological processes of breast cancer. We provided clues for furtherly investigating the role of lipid alterations in the pathoetiology of breast cancer.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"37 4","pages":"289-297"},"PeriodicalIF":3.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9950178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pyrimidinergic receptor P2Y6 expression is elevated in lung adenocarcinoma and is associated with poor prognosis. 嘧啶能受体P2Y6在肺腺癌中表达升高，与预后不良有关。

IF 3.1 4区医学

Cancer Biomarkers Pub Date : 2023-01-01 DOI: 10.3233/CBM-230137

Xiuli Wang, Baoshan Zhao, Dan Ren, Xiaolei Hu, Juanjuan Qiao, Dongmei Zhang, Yanzhi Zhang, Yu Pan, Yuhua Fan, Lili Liu, Xiaoxue Wang, Huanhuan Ma, Xueling Jia, Sihang Song, Chong Zhao, Jingbo Liu, Lin Wang

{"title":"Pyrimidinergic receptor P2Y6 expression is elevated in lung adenocarcinoma and is associated with poor prognosis.","authors":"Xiuli Wang, Baoshan Zhao, Dan Ren, Xiaolei Hu, Juanjuan Qiao, Dongmei Zhang, Yanzhi Zhang, Yu Pan, Yuhua Fan, Lili Liu, Xiaoxue Wang, Huanhuan Ma, Xueling Jia, Sihang Song, Chong Zhao, Jingbo Liu, Lin Wang","doi":"10.3233/CBM-230137","DOIUrl":"10.3233/CBM-230137","url":null,"abstract":"Backgroud: Previous in vitro studies have indicated that pyrimidinergic receptor P2Y6 (P2RY6, P2Y6 receptor) may function as a cancer-promoting factor in lung adenocarcinoma (LUAD). However, the prognostic significance of P2RY6 expression in LUAD has not been investigated.Objective: This study aimed to assess the impact of P2RY6 expression on the survival of patients with LUAD.Methods: First, we assessed P2RY6 mRNA and protein expression in LUAD and non-cancerous lung tissues using the online bioinformatics analysis tool GEPIA, fresh LUAD tissues, and LUAD tissue microarrays (TMAs). Second, we investigated the correlation between P2RY6 expression and clinicopathological parameters of LUAD patients based on data from The Cancer Genome Atlas (TCGA) database and TMAs. Finally, we analyzed the prognostic significance of P2RY6 expression in LUAD using the online survival analysis tool Kaplan-Meier Plotter and data from TMAs.Results: We demonstrated that P2RY6 mRNA and protein expression levels in LUAD tissues were significantly higher than those in non-cancerous lung tissues. The expression of P2RY6 in LUAD was positively correlated with poor differentiation, more lymph node metastasis, and more advanced clinical stage. Higher P2RY6 expression level was correlated with shorter survival of the LUAD patients. Univariate and multivariate Cox regression analyses indicated that higher P2RY6 tumor expression was an independent unfavorable prognostic factor for LUAD patients.Conclusions: P2RY6 expression was elevated in LUAD and correlated with poor prognosis.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":" ","pages":"191-201"},"PeriodicalIF":3.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10000595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma. TRB cdr3 -癌睾丸抗原化学互补评分用于鉴别肾细胞癌的生产性免疫反应。

IF 3.1 4区医学

Cancer Biomarkers Pub Date : 2023-01-01 DOI: 10.3233/CBM-230047

Tabitha R Hudock, Vayda R Barker, Brandon J Manley, Andrea Chobrutskiy, Boris I Chobrutskiy, Michael J Diaz, Joanna J Song, George Blanck

{"title":"TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma.","authors":"Tabitha R Hudock, Vayda R Barker, Brandon J Manley, Andrea Chobrutskiy, Boris I Chobrutskiy, Michael J Diaz, Joanna J Song, George Blanck","doi":"10.3233/CBM-230047","DOIUrl":"https://doi.org/10.3233/CBM-230047","url":null,"abstract":"Background: Immunogenomics approaches to the characterization of renal cell carcinoma (RCC) have helped to better our understanding of the features of RCC immune dysfunction. However, much is still unknown with regard to specific immune interactions and their impact in the tumor microenvironment.Objective: This study applied chemical complementarity scoring for the TRB complementarity determining region-3 (CDR3) amino acid sequences and cancer testis antigens (CTAs) to determine whether such complementarity correlated with survival and the expression of immune marker genes.Methods: TRB recombination reads from RCC tumor samples from RNAseq files obtained from two separate databases, Moffitt Cancer Center and The Cancer Genome Atlas (TCGA), were evaluated. Chemical complementarity scores (CSs) were calculated for TRB CDR3-CTA pairs and survival assessments based on those CSs were performed.Results: Moffitt Cancer Center and TCGA cases representing the upper 50th percentile of chemical CSs for TRB CDR3 amino acid sequences and the CTA POTEA were found to be associated with a better overall survival (OS) Also, greater tumor RNA expression of multiple immune signature genes, including granzyme A, granzyme B, and interferon-gamma were correlated with the higher chemical CSs.Conclusions: These results indicate that TRB CDR3-CTA chemical complementarity scoring may be useful in distinguishing RCC cases with a productive, anti-tumor immune response from cases where basic immune parameter assessments are inconsistent with a productive immune response.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"38 1","pages":"103-110"},"PeriodicalIF":3.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10209315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of ALK overexpression and molecular abnormalities in high-grade serous ovarian carcinoma. 高级别浆液性卵巢癌中ALK过表达及分子异常的预后价值。

IF 3.1 4区医学

Cancer Biomarkers Pub Date : 2023-01-01 DOI: 10.3233/CBM-230117

Adam Gorczyński, Kevin Miszewski, Yann Gager, Sonja Koch, Jane Pötschke, Dimitar Ugrinovski, Jörg Gabert, Agata Pospieszyńska, Dariusz Wydra, Renata Duchnowska, Bartosz Szymanowski, Szczepan Cierniak, Irene Kruecken, Karsten Neumann, Katarina Mirkov, Wojciech Biernat, Piotr Czapiewski

{"title":"Prognostic value of ALK overexpression and molecular abnormalities in high-grade serous ovarian carcinoma.","authors":"Adam Gorczyński, Kevin Miszewski, Yann Gager, Sonja Koch, Jane Pötschke, Dimitar Ugrinovski, Jörg Gabert, Agata Pospieszyńska, Dariusz Wydra, Renata Duchnowska, Bartosz Szymanowski, Szczepan Cierniak, Irene Kruecken, Karsten Neumann, Katarina Mirkov, Wojciech Biernat, Piotr Czapiewski","doi":"10.3233/CBM-230117","DOIUrl":"https://doi.org/10.3233/CBM-230117","url":null,"abstract":"Background: ALK receptor tyrosine kinase (ALK) aberrations have an established role in pathogenesis of many neoplasms, but their clinical significance in high grade serous ovarian carcinoma (HGSOC) is unclear.Objective: To analyse the frequency of ALK overexpression, molecular abnormalities of ALK, and their impact on the progression-free survival (PFS) and overall survival (OS) in HGSOC.Methods: Protein expression was examined by immunohistochemistry (IHC) using three different clones of anti-ALK antibody. The presence of translocations was analysed using fluorescent in situ hybridization. Next-generation sequencing was used for studying the copy number variation, as well as point mutation and translocations involving other commonly rearranged genes.Results: ALK overexpression was demonstrated in up to 52% of tumours, whereas ALK copy gains in 8.2%, with no clear impact on survival. ALK point mutations were identified in 13 tumours (8.9%), with 3 belonging to the class IV showing significantly better OS. A trend suggesting better PFS was also noticed in these cases. Additionally, three gene fusions were found: ERBB2-GRB7, PRKCA-BRCA1 and SND1-BRAF, none of which has been previously described in HGSOC.Conclusions: HGSOC harbouring activating ALK mutations might be associated with a better survival, while ALK overexpression and ALK amplification does not impact the prognosis.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"38 1","pages":"17-26"},"PeriodicalIF":3.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10211219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prediction for recurrent non-muscle invasive bladder cancer. 非肌性浸润性膀胱癌复发的预测。

IF 3.1 4区医学

Cancer Biomarkers Pub Date : 2023-01-01 DOI: 10.3233/CBM-220373

Keqiang Li, Aravind Raveendran, Guoqing Xie, Yu Zhang, Haofan Wu, Zhenlin Huang, Zhankui Jia, Jinjian Yang

引用次数: 0

Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib. Rs9679162基因型预测索拉非尼治疗晚期肝癌的预后

IF 3.1 4区医学

Cancer Biomarkers Pub Date : 2023-01-01 DOI: 10.3233/CBM-220042

Chih-Lang Lin, Rong-Nan Chien, Li-Wei Chen, Yu-De Chu, Chau-Ting Yeh

{"title":"Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.","authors":"Chih-Lang Lin, Rong-Nan Chien, Li-Wei Chen, Yu-De Chu, Chau-Ting Yeh","doi":"10.3233/CBM-220042","DOIUrl":"https://doi.org/10.3233/CBM-220042","url":null,"abstract":"Background: Sorafenib and lenvatinib are tyrosine kinase inhibitors widely used in the targeted therapy to treat advanced hepatocellular carcinoma (aHCC). The GALNT14-rs9679162 genotype is a predictor of therapeutic outcome in multiple gastrointestinal cancers.Objective: To investigate the predictive role of the GALNT14-rs9679162 genotype in aHCC treated with sorafenib or lenvatinib.Methods: Totally 350 real-world patients with aHCC received sorafenib or lenvatinib were enrolled for GALNT14-rs9679162 genotyping and outcome analysis. Kaplan-Meier and Cox regression analysis were conducted to evaluate therapeutic outcomes. Cell-based assays were performed to determine the underlying mechanism.Results: Kaplan-Meier and Cox regression analysis showed that the \"GG\" genotype was not associated with overall survival (OS) when all patients were included. However, it was associated with shorter OS in specific clinical subgroups, including anti-hepatitis C virus antibody-positive (n= 108; P= 0.005) and hepatitis B surface antigen-negative (n= 117; P= 0.002) patients. Intriguingly, hepatitis B virus X protein trans-suppressed the GALNT14 promoter, thereby reducing the elevated expression of GALNT14 in hepatoma cells, which partially contributed to the inability of the GALNT14-rs9679162 genotypes to predict the outcome of hepatitis B-related HCC. Finally, by analyzing the outcomes of 52 patients with aHCC treated with lenvatinib, patients with the \"GG\" genotype were associated with a favorable/shorter time-to-response (P= 0.013).Conclusions: The GALNT14-rs9679162 \"GG\" genotype predicted shorter OS in patients with HBsAg-negative aHCC treated with sorafenib, but predicted a favorable response in all patients with aHCC treated with lenvatinib.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"36 3","pages":"251-266"},"PeriodicalIF":3.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9593346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MKRN1/2 serve as tumor suppressors in renal clear cell carcinoma by regulating the expression of p53. MKRN1/2通过调控p53的表达在肾透明细胞癌中起抑瘤作用。

IF 3.1 4区医学

Cancer Biomarkers Pub Date : 2023-01-01 DOI: 10.3233/CBM-210559

Yun Yang, Yanyan Luo, Shuting Huang, Yonghui Tao, Chuanyin Li, Chengcheng Wang

{"title":"MKRN1/2 serve as tumor suppressors in renal clear cell carcinoma by regulating the expression of p53.","authors":"Yun Yang, Yanyan Luo, Shuting Huang, Yonghui Tao, Chuanyin Li, Chengcheng Wang","doi":"10.3233/CBM-210559","DOIUrl":"https://doi.org/10.3233/CBM-210559","url":null,"abstract":"Background: Kidney renal clear cell carcinoma (KIRC) belongs to renal cell carcinoma which is a very aggressive malignant tumor with poor prognosis and high mortality. The MKRN family includes three members MKRN1, MKRN2 and MKRN3, which are closely related to cancers, and have been involved in many studies.Objective: This study aimed to explore the roles of MKRN family in KIRC.Methods: The expression of MKRNs was analyzed using the UALCAN database, prognostic analysis was performed with the GEPIA2 and Kaplan-Meier Plotter database, and correlation analysis was assessed by GEPIA2. The CCK-8 and colony formation assay were performed to detect cell proliferation, wound healing assays were performed to detect cell migration, cell cycles were detected by flow cytometry analysis, GST pull-down and co-immunoprecipitation assays were performed to detect the interaction of proteins, and the expression of MKRNs, p53 and other proteins were detect by immunoblotting analysis or quantitative PCR (qPCR).Results: MKRN1 and MKRN2 were lowly expressed in KIRC samples compared to the corresponding normal tissues, and KIRC patients with high levels of MKRN1 and MKRN2 showed higher overall survival (OS) and disease free survival (DFS) rates. The overexpression of MKRN1 and MKRN2 inhibited the proliferation of human KIRC cells by arresting the cell cycles, but shows little effect on cells migration. The expression of MKRN1 and MKRN2 are correlated, and MKRN1 directly interacts with MKRN2. Moreover, both MKRN1 and MKRN2 were closely correlated with the expression of TP53 in KIRC tumor, and promoted the expression of p53 both at protein and mRNA levels.Conclusions: Our study suggests that MKRN1 and MKRN2 serve as tumor suppressors in KIRC, and act as promising therapeutic targets for KIRC treatment.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"36 4","pages":"267-278"},"PeriodicalIF":3.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9654188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum to: Comprehensive serum lipidomic analyses reveal potential biomarkers for malignant breast cancer: A case-control study. 全面的血清脂质组学分析揭示了恶性乳腺癌的潜在生物标志物:一项病例对照研究。

IF 3.1 4区医学

Cancer Biomarkers Pub Date : 2023-01-01 DOI: 10.3233/CBM-239003

引用次数: 0